- Trials with a EudraCT protocol (73)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
73 result(s) found for: Anaplastic Lymphoma Kinase.
Displaying page 1 of 4.
EudraCT Number: 2010-020363-21 | Sponsor Protocol Number: SGN35-010 | Start Date*: 2010-11-09 | |||||||||||
Sponsor Name:Seattle Genetics, Inc. | |||||||||||||
Full Title: An open-label, phase 2/3, treatment-option protocol of brentuximab vedotin in patients with progression of Hodgkin lymphoma | |||||||||||||
Medical condition: Patients who were on the placebo arm and experienced progression of HL while participating in the SGN35-005 clinical study | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) HU (Completed) CZ (Completed) ES (Completed) IT (Completed) BG (Completed) BE (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006035-12 | Sponsor Protocol Number: SG035-0004 | Start Date*: 2009-03-24 | |||||||||||
Sponsor Name:Seattle Genetics, Inc. | |||||||||||||
Full Title: A Phase 2 study of SGN-35 in treatment of patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) | |||||||||||||
Medical condition: Systemic anaplastic large cell lymphoma (ALCL) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) IT (Completed) FR (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005547-26 | Sponsor Protocol Number: MDX060-04 | Start Date*: 2007-03-13 |
Sponsor Name:Medarex, Inc. | ||
Full Title: An Open-label, Fixed-dose, Multicenter, Phase II Study of MDX-060 in Patients with Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma | ||
Medical condition: Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma (ALCL) | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2012-002074-31 | Sponsor Protocol Number: CLDK378X2103 | Start Date*: 2013-11-13 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A Phase I, open-label, dose escalation study of LDK378 in pediatric patients with malignancies that have a genetic alteration in anaplastic lymphoma kinase (ALK) | ||
Medical condition: malignancies characterized by genetic abnormalities in anaplastic lymphoma kinase (ALK) | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) NL (Completed) GB (Completed) IT (Completed) FR (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-003468-19 | Sponsor Protocol Number: ADVL0912 | Start Date*: 2020-08-14 |
Sponsor Name:Children’s Oncology Group | ||
Full Title: ADVL0912: A PHASE 1/2 STUDY OF PF02341066, AN ORAL SMALL MOLECULE INHIBITOR OF ANAPLASTIC LYMPHOMA KINASE (ALK) AND C-MET, IN CHILDREN WITH RELAPSED/REFRACTORY SOLID TUMORS AND ANAPLASTIC LARGE CEL... | ||
Medical condition: malignant solid tumors including Inflammatory myofibroblastic tumor (IMT) and anaplastic large-cell lymphoma (ALCL) | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2017-000241-49 | Sponsor Protocol Number: CNIR178X2201 | Start Date*: 2017-12-05 | ||||||||||||||||
Sponsor Name:Novartis Pharma AG | ||||||||||||||||||
Full Title: A Phase 2, multi-center, open label study of NIR178 in combination with PDR001 in patients with selected advanced solid tumors and non-Hodgkin lymphoma | ||||||||||||||||||
Medical condition: Advanced solid tumors and non-Hodgkin lymphoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) BE (Completed) CZ (Completed) AT (Prematurely Ended) ES (Prematurely Ended) NL (Completed) FR (Prematurely Ended) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-022978-14 | Sponsor Protocol Number: A8081013 | Start Date*: 2011-02-10 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: PHASE 1B OPEN-LABEL STUDY OF THE SAFETY AND CLINICAL ACTIVITY OF CRIZOTINIB (PF-02341066) IN TUMORS WITH GENETIC EVENTS INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK ) GENE LOCUS | |||||||||||||
Medical condition: Treatment of tumors with translocation, mutation, or amplification of the anaplastic lymphoma kinase (ALK)gene locus. | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022230-81 | Sponsor Protocol Number: PDX-017 | Start Date*: 2011-04-05 | |||||||||||
Sponsor Name:Allos Therapeutics, Inc. | |||||||||||||
Full Title: A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients with Previously Undiagnosed Peripheral T-cell Lymphoma Who Have Achieved an Objective Response Fo... | |||||||||||||
Medical condition: Patients with previously undiagnosed peripheral T-cell lymphoma who have achieved an objective response following initial treatment with CHOP-based chemotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) CZ (Completed) IE (Completed) ES (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000634-29 | Sponsor Protocol Number: MO29750 | Start Date*: 2015-08-10 | ||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||
Full Title: RANDOMIZED, MULTICENTER, PHASE III, OPEN-LABEL STUDY OF ALECTINIB VERSUS PEMETREXED OR DOCETAXEL IN ANAPLASTIC LYMPHOMA KINASE-POSITIVE ADVANCED NON SMALL CELL LUNG CANCER PATIENTS PREVIOUSLY TREAT... | ||||||||||||||||||
Medical condition: Anaplastic lymphoma kinase-positive (ALK-positive) non-small cell lung cancer (NSCLC) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: PT (Completed) ES (Completed) DE (Completed) SK (Completed) HU (Completed) FR (Completed) PL (Completed) BE (Completed) BG (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-001240-29 | Sponsor Protocol Number: C25002 | Start Date*: 2012-04-24 | ||||||||||||||||
Sponsor Name:Millennium Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Phase 1/2 Study of Brentuximab Vedotin (SGN-35) in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma | ||||||||||||||||||
Medical condition: Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) GB (Completed) NL (Completed) IT (Completed) ES (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-000635-27 | Sponsor Protocol Number: 2002 | Start Date*: 2018-10-10 | |||||||||||
Sponsor Name:ARIAD Pharmaceuticals, Inc.(a wholly-owned subsidiary of Takeda Pharmaceutical Ltd.) | |||||||||||||
Full Title: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non–Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib | |||||||||||||
Medical condition: Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non–Small-Cell Lung Cancer (NSCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DE (Completed) ES (Completed) AT (Completed) NL (Ongoing) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004331-37 | Sponsor Protocol Number: BO40336 | Start Date*: 2018-06-21 | ||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||
Full Title: A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ALECTINIB VERSUS ADJUVANT PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB (TUMORS... | ||||||||||||||||||
Medical condition: Completely resected, Stage IB (tumors ≥4 cm) to Stage IIIA, Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC). | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: LV (Completed) GR (Ongoing) DE (Ongoing) AT (Ongoing) GB (GB - no longer in EU/EEA) PT (Completed) PL (Ongoing) ES (Ongoing) HU (Ongoing) DK (Ongoing) IT (Ongoing) RO (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-012595-27 | Sponsor Protocol Number: A8081007 | Start Date*: 2010-01-20 | |||||||||||
Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF PF 02341066 VERSUS STANDARD OF CARE CHEMOTHERAPY (PEMETREXED OR DOCETAXEL) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (... | |||||||||||||
Medical condition: ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) NL (Completed) DE (Completed) PL (Completed) ES (Completed) HU (Completed) FR (Completed) GR (Completed) IT (Completed) IE (Completed) BG (Completed) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000814-23 | Sponsor Protocol Number: CLDK378A2407 | Start Date*: 2015-10-26 |
Sponsor Name:Novartis Farmacéutica, S.A. | ||
Full Title: A Phase II, open label, multi-center, multi-arm study of ceritinib in patients with advanced solid tumors and hematological malignancies characterized by genetic abnormalities of anaplastic lymphom... | ||
Medical condition: Advanced solid tumors and hematological malignancies with ALK genetic alteration and/or overexpression | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) DE (Temporarily Halted) CZ (Completed) FR (Prematurely Ended) DK (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2010-021091-28 | Sponsor Protocol Number: AB10004 | Start Date*: 2014-12-18 | |||||||||||
Sponsor Name:AB Science | |||||||||||||
Full Title: A multicenter, randomised, open-label, three-parallel groups, phase 2-3 study to evaluate the efficacy and safety of masitinib with dexamethasone, gemcitabine with dexamethasone and the combination... | |||||||||||||
Medical condition: Relapsed or refractory Peripheral T-cell lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Ongoing) GR (Prematurely Ended) ES (Prematurely Ended) GB (Prematurely Ended) HU (Ongoing) SK (Prohibited by CA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000207-24 | Sponsor Protocol Number: BO39694 | Start Date*: 2017-05-16 | ||||||||||||||||
Sponsor Name:Roche Farma S.A.U. que realiza el ensayo en España y que actúa como representante de F.Hoffmann-La Roche Ltd. | ||||||||||||||||||
Full Title: A MULTICENTER, INTERNATIONAL, ROLLOVER STUDY OF ALECTINIB IN PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE OR REARRANGED DURING TRANSFECTION (RET)-POSITIVE CANCER | ||||||||||||||||||
Medical condition: Anaplastic lymphoma kinase (ALK)-positive or rearranged during transfection (RET)-positive cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) FR (Ongoing) PL (Completed) IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001456-34 | Sponsor Protocol Number: CTMX-M-2029-001 | Start Date*: 2019-01-17 | |||||||||||||||||||||||||||||||
Sponsor Name:CytomX Therapeutics, Inc. | |||||||||||||||||||||||||||||||||
Full Title: A Phase 1-2, First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas | |||||||||||||||||||||||||||||||||
Medical condition: Metastatic or locally advanced unresectable solid tumor or diffuse large B-cell lymphoma | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: ES (Ongoing) GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002990-84 | Sponsor Protocol Number: MOR208C310 | Start Date*: 2021-03-01 | ||||||||||||||||
Sponsor Name:MorphoSys AG | ||||||||||||||||||
Full Title: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untre... | ||||||||||||||||||
Medical condition: Newly-diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma (DLBCL). | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Trial now transitioned) IE (Ongoing) DE (Trial now transitioned) CZ (Trial now transitioned) SK (Trial now transitioned) HU (Ongoing) AT (Ongoing) IT (Ongoing) RO (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-012504-13 | Sponsor Protocol Number: A8081005 | Start Date*: 2010-01-20 | |||||||||||
Sponsor Name:Pfizer Inc 235 East 42nd Street, New York, NY10017 | |||||||||||||
Full Title: PHASE 2, OPEN-LABEL SINGLE ARM STUDY OF THE EFFICACY AND SAFETY OF PF 02341066 IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING A TRANSLOCATION OR INVERSION INVOLVING THE ANAP... | |||||||||||||
Medical condition: metastatic non-small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) NL (Completed) DE (Completed) ES (Completed) HU (Completed) PL (Completed) GR (Completed) IT (Completed) FR (Completed) IE (Completed) BG (Completed) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003700-44 | Sponsor Protocol Number: BGB-A317-207 | Start Date*: 2018-06-21 | |||||||||||
Sponsor Name:BeiGene, Ltd. c/o BeiGene USA, Inc. | |||||||||||||
Full Title: A Phase 2, Open-Label Study of BGB-A317 in Patients with Relapsed or Refractory Mature T- and NK-cell Neoplasms | |||||||||||||
Medical condition: Relapsed or Refractory Mature T- and NK-cell Neoplasms | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.